Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic.
J Chin Med Assoc. 2021 01 01; 84(1):9-13.JC

Abstract

The pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has brought an unprecedented impact upon the global economy and public health. Although the SARS-CoV-2 virology has been gradually investigated, measures to combat this new threat in public health are still absent. To date, no certificated drug or vaccine has been developed for the treatment or prevention of coronavirus disease Extensive researches and international coordination has been conducted to rapidly develop novel vaccines against SARS-CoV-2 pandemic. Several major breakthroughs have been made through the identification of the genetic sequence and structural/non-structural proteins of SARS-CoV-2, which enabled the development of RNA-, DNA-based vaccines, subunit vaccines, and attenuated viral vaccines. In this review article, we present an overview of the recent advances of SARS-CoV-2 vaccines and the challenges that may be encountered in the development process, highlighting the advantages and disadvantages of these approaches that may help in effectively countering COVID-19.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Liu CH
Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, ROC.
Huang HY
Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Tu YF
Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, ROC.
Lai WY
Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Wang CL
Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Sun JR
Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan, ROC.
Chien Y
Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Lin TW
Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Lin YY
Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Chien CS
Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Huang CH
Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan, ROC.
Chen YM
School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, ROC. Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Huang PI
School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, ROC. Division of Radiation Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Wang FD
School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, ROC. Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Yang YP
Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, ROC.

MeSH

COVID-19COVID-19 VaccinesHumansSARS-CoV-2Vaccines, DNAVaccines, SubunitVaccines, Synthetic

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

33186212